Docket Number:28A- 1041012
Inventor:Jean Lu, Hsiao-Chun Huang, Pei-Lun Lai
IP Status:TW 、US pending
Abstract:
Mesenchymal stem/stroma cells (MSCs) have great potential in the treatment of multiple diseases. However, it is hard to obtain sufficient amounts of autologous or HLA-matched allogenic MSCs. Here, we develop the first, new, safe, and efficient method to generate induced MSCs (iMSCs) from somatic cells with chemicals (in the present or absence of growth factors). The conversion rate of somatic cells to iMSCs is as high as 40% and this protocol only need 6 days. This finding may overcome the obstacles of obtaining sufficient autologous or allogenic MSCs for cell therapy.
Fields of Application:
- A commercial kit for generating iMSCs.
- Generation of undifferentiated iMSCs for disease treatments.
- Production of specific functional cells from iMSCs for tissue engineering and regenerative medicine.
- In vivo reprogramming of somatic cells into iMSCs.
Advantages when compared to the existing technologies:
- The first method to generate induced MSCs (iMSCs) from differentiated somatic cells.
- The first chemical cocktail able to reprogram/de-differentiate somatic cells into iMSCs. No prior technology can generate MSCs from any other somatic cell types with soluble factors like chemicals and/or growth factors.
- iMSCs are generated with a few chemicals (with or without growth factors) within 6 days.
- iMSCs conversion rate from somatic cells is high. The average efficiency is 37.6%.
- Both neonatal fibroblasts and adult skin fibroblasts can be converted into functional iMSCs. Of note, it is hard to isolate functional and expandable MSCs from elderly patients.
- iMSCs, like MSCs, are expandable for at least 8 passages.
- The components of cocktails for generating iMSCs are all well-defined and do not contain animal serum, which is suitable for clinical applications and has high reproducibility.
- iMSCs, like MSCs, are multipotent and can differentiate into multiple functional cell types.
- iMSCs, like MSCs, have immunomodulation functions and can treat diseases in the animal models.
- All iMSCs share the same molecular signatures with MSCs.
- The reprogramming process only requires chemicals (with or without growth factors). No retrovirus/lentivirus/plasmid is required for the dedifferentiation process, which avoids insertional mutagenesis or other biosafety concerns.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
